Accueil > Résultats de la recherche > Suite de la publication

Leucémie myéloïdechroniquedessujets jeunes :expériencedansuneunité d’hématologie cliniqueauSénégal

Summary Purpose.— As farasweknow,thereisnotyetanystudyavailableaboutchronicmyeloid leukemia inchildrenandadolescentsinsub-SaharanAfrica.Inordertodescribeitsclinical, cytogenetic, prognostic,andevolvingcharacteristics,weconductedaretrospectivedescriptive study during6years(February2008—July2014). Method.— This studywasconductedintheHematologyClinicalUnitoftheAristideLeDantec Hospital (Senegal)involvingpatientsaged17yearsormore,sufferingfromchronicmyeloid leukemia, treatedusingImatinibMesylate. Results.— Nine ofthe87patients(10.4%)wereincludedinthestudy.Thesewere7boysand 2 girls,whosemedianagewas14years[9—17years].Theywerereceivedineitherthechronic phase (7cases)ortheacceleratedphase(2cases).Themediandiagnosticdelaywas19months [2—54 months].TheSokalscorewaslow(4cases),intermediate(3cases)andhigh(2cases). One patienthadalsoatrisomy8.Theoveralltrendwasmarkedbyacompletecytogenetic remission in6cases,apartialremissionin2casesandaminorremissionintheremainingcase. Twopatientslosttheresponsetothetreatment,withamutationofBCR-Abelsonobjectifiedin 1 case.Toxiceffectswerevomiting(1case),diffusedepigmentation(1case)andthrombocyto- penia (2cases). Conclusion.— In ourstudy,chronicmyeloidleukemiainchildrenandadolescentsisuncommon and isdiagnosedlate.ImatinibMesylateiseffective,butthelossofresponserelatedtomuta- tions, requiredtheuseofothertyrosinekinaseinhibitorsand/orbonemarrowtransplantation, which arenotavailableinourregions. © 2015ElsevierMassonSAS.Allrightsreserved.


Auteur(s) : S. Fall a,?, F.S.D.Ndiayea, O.D.Diora, A.F.Sall b, I. Slomac, A.Touré-Fall b, Y.Keitad
Année de publication : 2015
Type : Article
Mise en ligne par : KEITA Younoussa